Trial Profile

A Randomized, Double-blind, Active Control,parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fimasartan (Primary) ; Losartan
Indications Diabetic nephropathies; Hypertension; Renal failure
Focus Therapeutic Use
Acronyms FANTASTIC
Sponsors Boryung Pharmaceutical

Most Recent Events

01 Dec 2022 Results published in the Hypertension Research
24 May 2022 Status changed from active, no longer recruiting to completed.
16 Sep 2019 Planned End Date changed from 1 Dec 2020 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com